Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration.

Tobin JWD, Keane C, Gunawardana J, Mollee P, Birch S, Hoang T, Lee J, Li L, Huang L, Murigneux V, Fink JL, Matigian N, Vari F, Francis S, Kridel R, Weigert O, Haebe S, Jurinovic V, Klapper W, Steidl C, Sehn LH, Law SC, Wykes MN, Gandhi MK.

J Clin Oncol. 2019 Aug 28:JCO1802365. doi: 10.1200/JCO.18.02365. [Epub ahead of print]

PMID:
31461379
2.

Impact of age on clinical risk scores in follicular lymphoma.

Alig S, Jurinovic V, Pastore A, Haebe S, Schmidt C, Zoellner AK, Dreyling M, Unterhalt M, Hoster E, Hiddemann W, Weigert O.

Blood Adv. 2019 Apr 9;3(7):1033-1038. doi: 10.1182/bloodadvances.2019032136.

3.

Convergence of risk prediction models in follicular lymphoma.

Silva A, Bassim S, Sarkozy C, Mottok A, Lackraj T, Jurinovic V, Brodtkorb M, Lingjaerde OC, Sehn LH, Gascoyne RD, Weigert O, Steidl C, Kridel R.

Haematologica. 2019 Jun;104(6):e252-e255. doi: 10.3324/haematol.2018.209031. Epub 2019 Jan 3. No abstract available.

4.

Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016.

Qu X, Li H, Braziel RM, Passerini V, Rimsza LM, Hsi ED, Leonard JP, Smith SM, Kridel R, Press O, Weigert O, LeBlanc M, Friedberg JW, Fang M.

Blood. 2019 Jan 3;133(1):81-93. doi: 10.1182/blood-2018-07-865428. Epub 2018 Nov 16.

PMID:
30446494
5.

Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles.

Hellmuth JC, Louissaint A Jr, Szczepanowski M, Haebe S, Pastore A, Alig S, Staiger AM, Hartmann S, Kridel R, Ducar MD, Koch P, Dreyling M, Hansmann ML, Ott G, Rosenwald A, Gascoyne RD, Weinstock DM, Hiddemann W, Klapper W, Weigert O.

Blood. 2018 Oct 18;132(16):1695-1702. doi: 10.1182/blood-2018-03-837252. Epub 2018 Aug 20.

PMID:
30126979
6.

Correction to: DNA methylation-based reclassification of olfactory neuroblastoma.

Capper D, Engel NW, Stichel D, Lechner M, Glöss S, Schmid S, Kölsche C, Schrimpf D, Niesen J, Wefers AK, Jones DTW, Sill M, Weigert O, Ligon KL, Olar A, Koch A, Forster M, Moran S, Tirado OM, Sáinz-Jaspeado M, Mora J, Esteller M, Alonso J, Del Muro XG, Paulus W, Felsberg J, Reifenberger G, Glatzel M, Frank S, Monoranu CM, Lund VJ, von Deimling A, Pfister S, Buslei R, Ribbat-Idel J, Perner S, Gudziol V, Meinhardt M, Schüller U.

Acta Neuropathol. 2018 Sep;136(3):505. doi: 10.1007/s00401-018-1887-y.

PMID:
30094618
7.

DNA methylation-based reclassification of olfactory neuroblastoma.

Capper D, Engel NW, Stichel D, Lechner M, Glöss S, Schmid S, Koelsche C, Schrimpf D, Niesen J, Wefers AK, Jones DTW, Sill M, Weigert O, Ligon KL, Olar A, Koch A, Forster M, Moran S, Tirado OM, Sáinz-Jaspeado M, Mora J, Esteller M, Alonso J, Del Muro XG, Paulus W, Felsberg J, Reifenberger G, Glatzel M, Frank S, Monoranu CM, Lund VJ, von Deimling A, Pfister S, Buslei R, Ribbat-Idel J, Perner S, Gudziol V, Meinhardt M, Schüller U.

Acta Neuropathol. 2018 Aug;136(2):255-271. doi: 10.1007/s00401-018-1854-7. Epub 2018 May 5. Erratum in: Acta Neuropathol. 2018 Sep;136(3):505.

PMID:
29730775
8.

Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group.

Jurinovic V, Metzner B, Pfreundschuh M, Schmitz N, Wandt H, Keller U, Dreger P, Dreyling M, Hiddemann W, Unterhalt M, Hoster E, Weigert O.

Biol Blood Marrow Transplant. 2018 Jun;24(6):1172-1179. doi: 10.1016/j.bbmt.2018.03.022. Epub 2018 Mar 29.

9.

Impact of age on genetics and treatment efficacy in follicular lymphoma.

Alig S, Jurinovic V, Pastore A, Bararia D, Häbe S, Hellmuth JC, Kridel R, Gascoyne R, Schmidt C, Zöllner AK, Buske C, Dreyling M, Unterhalt M, Hiddemann W, Hoster E, Weigert O.

Haematologica. 2018 Aug;103(8):e364-e367. doi: 10.3324/haematol.2018.187773. Epub 2018 Mar 15. No abstract available.

10.

FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.

Mottok A, Jurinovic V, Farinha P, Rosenwald A, Leich E, Ott G, Horn H, Klapper W, Boesl M, Hiddemann W, Steidl C, Connors JM, Sehn LH, Gascoyne RD, Hoster E, Weigert O, Kridel R.

Blood. 2018 Jan 11;131(2):226-235. doi: 10.1182/blood-2017-08-799080. Epub 2017 Nov 9.

11.

Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells.

Body S, Esteve-Arenys A, Miloudi H, Recasens-Zorzo C, Tchakarska G, Moros A, Bustany S, Vidal-Crespo A, Rodriguez V, Lavigne R, Com E, Casanova I, Mangues R, Weigert O, Sanjuan-Pla A, Menéndez P, Marcq B, Picquenot JM, Pérez-Galán P, Jardin F, Roué G, Sola B.

Sci Rep. 2017 Oct 24;7(1):13946. doi: 10.1038/s41598-017-14222-1.

12.

The promises and challenges of using gene mutations for patient stratification in follicular lymphoma.

Weigert O, Weinstock DM.

Blood. 2017 Sep 28;130(13):1491-1498. doi: 10.1182/blood-2017-07-737353. Epub 2017 Aug 7. Review.

13.

Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015.

Gascoyne RD, Nadel B, Pasqualucci L, Fitzgibbon J, Payton JE, Melnick A, Weigert O, Tarte K, Gribben JG, Friedberg JW, Seymour JF, Cavalli F, Zucca E.

Hematol Oncol. 2017 Dec;35(4):397-407. doi: 10.1002/hon.2411. Epub 2017 Apr 4. Review.

PMID:
28378425
14.

It's a long way to the top (if you want to personalize immunotherapy).

Haebe S, Weigert O.

J Immunother Cancer. 2017 Jan 17;5:6. doi: 10.1186/s40425-016-0207-0. eCollection 2017.

15.

HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma.

Jacobson C, Kopp N, Layer JV, Redd RA, Tschuri S, Haebe S, van Bodegom D, Bird L, Christie AL, Christodoulou A, Saur A, Tivey T, Zapf S, Bararia D, Zimber-Strobl U, Rodig SJ, Weigert O, Weinstock DM.

Blood. 2016 Nov 24;128(21):2517-2526. Epub 2016 Oct 14.

16.

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy.

Jurinovic V, Kridel R, Staiger AM, Szczepanowski M, Horn H, Dreyling MH, Rosenwald A, Ott G, Klapper W, Zelenetz AD, Barr PM, Friedberg JW, Ansell S, Sehn LH, Connors JM, Gascoyne RD, Hiddemann W, Unterhalt M, Weinstock DM, Weigert O.

Blood. 2016 Aug 25;128(8):1112-20. doi: 10.1182/blood-2016-05-717355. Epub 2016 Jul 14.

17.

Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones.

Melchardt T, Hufnagl C, Weinstock DM, Kopp N, Neureiter D, Tränkenschuh W, Hackl H, Weiss L, Rinnerthaler G, Hartmann TN, Greil R, Weigert O, Egle A.

Oncotarget. 2016 Aug 9;7(32):51494-51502. doi: 10.18632/oncotarget.9860.

18.

Acetylation of C/EBPα inhibits its granulopoietic function.

Bararia D, Kwok HS, Welner RS, Numata A, Sárosi MB, Yang H, Wee S, Tschuri S, Ray D, Weigert O, Levantini E, Ebralidze AK, Gunaratne J, Tenen DG.

Nat Commun. 2016 Mar 23;7:10968. doi: 10.1038/ncomms10968.

19.

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.

Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, Pott C, Kopp N, Murakami M, Horn H, Leich E, Moccia AA, Mottok A, Sunkavalli A, Van Hummelen P, Ducar M, Ennishi D, Shulha HP, Hother C, Connors JM, Sehn LH, Dreyling M, Neuberg D, Möller P, Feller AC, Hansmann ML, Stein H, Rosenwald A, Ott G, Klapper W, Unterhalt M, Hiddemann W, Gascoyne RD, Weinstock DM, Weigert O.

Lancet Oncol. 2015 Sep;16(9):1111-1122. doi: 10.1016/S1470-2045(15)00169-2. Epub 2015 Aug 6.

PMID:
26256760
20.

Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial.

Ferrero S, Pastore A, Scholz CW, Forstpointner R, Pezzutto A, Bergmann L, Trümper L, Finke J, Keller U, Ghione P, Passera R, Hiddemann W, Weigert O, Unterhalt M, Dreyling M.

Leukemia. 2016 Apr;30(4):984-7. doi: 10.1038/leu.2015.215. Epub 2015 Aug 5. No abstract available.

PMID:
26242461
21.

Mutations in G protein β subunits promote transformation and kinase inhibitor resistance.

Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu SC, Kim SS, Liu H, Tivey T, Christie AL, Elpek KG, Card J, Gritsman K, Gotlib J, Deininger MW, Makishima H, Turley SJ, Javidi-Sharifi N, Maciejewski JP, Jaiswal S, Ebert BL, Rodig SJ, Tyner JW, Marto JA, Weinstock DM, Lane AA.

Nat Med. 2015 Jan;21(1):71-5. doi: 10.1038/nm.3751. Epub 2014 Dec 8.

22.

A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.

Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, Kim S, van Bodegom D, Bolla S, Schatz JH, Teruya-Feldstein J, Hochberg E, Louissaint A, Dorfman D, Stevenson K, Rodig SJ, Piccaluga PP, Jacobsen E, Pileri SA, Harris NL, Ferrero S, Inghirami G, Horwitz SM, Weinstock DM.

Blood. 2014 Feb 27;123(9):1293-6. doi: 10.1182/blood-2013-10-531509. Epub 2013 Dec 17.

23.

Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry.

Kluk MJ, Ashworth T, Wang H, Knoechel B, Mason EF, Morgan EA, Dorfman D, Pinkus G, Weigert O, Hornick JL, Chirieac LR, Hirsch M, Oh DJ, South AP, Leigh IM, Pourreyron C, Cassidy AJ, Deangelo DJ, Weinstock DM, Krop IE, Dillon D, Brock JE, Lazar AJ, Peto M, Cho RJ, Stoeck A, Haines BB, Sathayanrayanan S, Rodig S, Aster JC.

PLoS One. 2013 Jun 18;8(6):e67306. doi: 10.1371/journal.pone.0067306. Print 2013.

24.

CD4+Foxp3+ regulatory T cells prolong drug-induced disease remission in (NZBxNZW) F1 lupus mice.

Weigert O, von Spee C, Undeutsch R, Kloke L, Humrich JY, Riemekasten G.

Arthritis Res Ther. 2013 Feb 27;15(1):R35. doi: 10.1186/ar4188.

25.

Next-generation cDNA screening for oncogene and resistance phenotypes.

Shindoh N, Yoda A, Yoda Y, Sullivan TJ, Weigert O, Lane AA, Kopp N, Bird L, Rodig SJ, Fox EA, Weinstock DM.

PLoS One. 2012;7(11):e49201. doi: 10.1371/journal.pone.0049201. Epub 2012 Nov 7.

26.

Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2.

van Bodegom D, Zhong J, Kopp N, Dutta C, Kim MS, Bird L, Weigert O, Tyner J, Pandey A, Yoda A, Weinstock DM.

Blood. 2012 Oct 4;120(14):2853-63. doi: 10.1182/blood-2012-02-413252. Epub 2012 Aug 20.

27.

The evolving contribution of hematopoietic progenitor cells to lymphomagenesis.

Weigert O, Weinstock DM.

Blood. 2012 Sep 27;120(13):2553-61. Epub 2012 Aug 6. Review.

28.

BCL2 suppresses PARP1 function and nonapoptotic cell death.

Dutta C, Day T, Kopp N, van Bodegom D, Davids MS, Ryan J, Bird L, Kommajosyula N, Weigert O, Yoda A, Fung H, Brown JR, Shapiro GI, Letai A, Weinstock DM.

Cancer Res. 2012 Aug 15;72(16):4193-203. doi: 10.1158/0008-5472.CAN-11-4204. Epub 2012 Jun 11.

29.

Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation.

Weigert O, Kopp N, Lane AA, Yoda A, Dahlberg SE, Neuberg D, Bahar AY, Chapuy B, Kutok JL, Longtine JA, Kuo FC, Haley T, Salois M, Sullivan TJ, Fisher DC, Fox EA, Rodig SJ, Antin JH, Weinstock DM.

Cancer Discov. 2012 Jan;2(1):47-55. doi: 10.1158/2159-8290.CD-11-0208. Epub 2011 Dec 12.

30.

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.

Weigert O, Lane AA, Bird L, Kopp N, Chapuy B, van Bodegom D, Toms AV, Marubayashi S, Christie AL, McKeown M, Paranal RM, Bradner JE, Yoda A, Gaul C, Vangrevelinghe E, Romanet V, Murakami M, Tiedt R, Ebel N, Evrot E, De Pover A, Régnier CH, Erdmann D, Hofmann F, Eck MJ, Sallan SE, Levine RL, Kung AL, Baffert F, Radimerski T, Weinstock DM.

J Exp Med. 2012 Feb 13;209(2):259-73. doi: 10.1084/jem.20111694. Epub 2012 Jan 23.

31.

The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.

Hutter G, Rieken M, Pastore A, Weigert O, Zimmermann Y, Weinkauf M, Hiddemann W, Dreyling M.

Ann Hematol. 2012 Jun;91(6):847-56. doi: 10.1007/s00277-011-1377-y. Epub 2012 Jan 11.

PMID:
22231280
32.

Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.

Ward PS, Cross JR, Lu C, Weigert O, Abel-Wahab O, Levine RL, Weinstock DM, Sharp KA, Thompson CB.

Oncogene. 2012 May 10;31(19):2491-8. doi: 10.1038/onc.2011.416. Epub 2011 Sep 26.

34.

Vincristine-loaded platelets for immune thrombocytopenia.

Weigert O, Wittmann G, Grützner S, Christ O, Christ B, Rank A, Ostermann H.

Thromb Haemost. 2010 Aug;104(2):418-9. doi: 10.1160/TH09-11-0752. Epub 2010 May 27. No abstract available.

PMID:
20508905
35.

Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus.

Humrich JY, Morbach H, Undeutsch R, Enghard P, Rosenberger S, Weigert O, Kloke L, Heimann J, Gaber T, Brandenburg S, Scheffold A, Huehn J, Radbruch A, Burmester GR, Riemekasten G.

Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):204-9. doi: 10.1073/pnas.0903158107. Epub 2009 Dec 14.

36.

Mantle cell lymphoma: state-of-the-art management and future perspective.

Weigert O, Unterhalt M, Hiddemann W, Dreyling M.

Leuk Lymphoma. 2009 Dec;50(12):1937-50. doi: 10.3109/10428190903288514. Review.

PMID:
19863180
37.

A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study.

Weigert O, Weidmann E, Mueck R, Bentz M, von Schilling C, Rohrberg R, Jentsch-Ullrich K, Hiddemann W, Dreyling M.

Leuk Lymphoma. 2009 May;50(5):716-22. doi: 10.1080/10428190902856790.

PMID:
19347767
38.

Prognosis of mantle cell lymphoma: is it all about proliferation?

Weigert O, Dreyling M.

Leuk Lymphoma. 2008 Nov;49(11):2029-30. doi: 10.1080/10428190802526964. No abstract available.

PMID:
19021041
39.

Successful salvage treatment of chronic refractory immune thrombocytopenia using a simplified method to generate vincristine-loaded platelets.

Weigert O, Wittmann G, Gruetzner S, Cnossen J, Becker MC, Dreyling M, Ostermann H.

Thromb Haemost. 2008 Oct;100(4):705-7. No abstract available.

PMID:
18841296
40.

Current treatment standards and future strategies in mantle cell lymphoma.

Dreyling M, Weigert O, Hiddemann W; European MCL Network.

Ann Oncol. 2008 Jun;19 Suppl 4:iv41-4. doi: 10.1093/annonc/mdn193. Review. No abstract available.

PMID:
18519401
41.

Current management of mantle cell lymphoma.

Weigert O, Unterhalt M, Hiddemann W, Dreyling M.

Drugs. 2007;67(12):1689-702. Review.

PMID:
17683170
42.

[Therapy of mantle cell lymphoma].

Dreyling M, Unterhalt M, Weigert O, Hiddemann W.

Internist (Berl). 2007 Apr;48(4):382-8. Review. German.

PMID:
17308912
43.

Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.

Weigert O, Pastore A, Rieken M, Lang N, Hiddemann W, Dreyling M.

Leukemia. 2007 Mar;21(3):524-8. Epub 2007 Feb 1.

PMID:
17268531
44.

Current management of follicular lymphomas.

Hiddemann W, Buske C, Dreyling M, Weigert O, Lenz G, Unterhalt M.

Br J Haematol. 2007 Jan;136(2):191-202. Epub 2006 Oct 31. Review.

PMID:
17073892
45.

Investigational strategies in autologous stem cell transplantation for follicular lymphoma.

Weigert O, Dreyling M, Unterhalt M, Hiddemann W, Buske C.

Curr Oncol Rep. 2006 Sep;8(5):368-75. Review.

PMID:
16901398
46.

Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma.

Weigert O, Illidge T, Hiddemann W, Dreyling M.

Cancer. 2006 Aug 15;107(4):686-95.

47.

Current status and perspective of antibody therapy in follicular lymphoma.

Buske C, Weigert O, Dreyling M, Unterhalt M, Hiddemann W.

Haematologica. 2006 Jan;91(1):104-12. Review.

48.

Treatment strategies in follicular lymphomas: current status and future perspectives.

Hiddemann W, Buske C, Dreyling M, Weigert O, Lenz G, Forstpointner R, Nickenig C, Unterhalt M.

J Clin Oncol. 2005 Sep 10;23(26):6394-9. Review.

PMID:
16155025
49.

Brain metastases in metastatic non-small cell lung cancer responding to single-agent gefitinib: a case report.

Stemmler HJ, Weigert O, Krych M, Schoenberg SO, Ostermann H, Hiddemann W.

Anticancer Drugs. 2005 Aug;16(7):747-9.

PMID:
16027524

Supplemental Content

Loading ...
Support Center